BioXcel Therapeutics Files Chapter 11, Agrees to Sell Assets to Teva

What happened

BioXcel Therapeutics, Inc. (NASDAQ: BTAI), a biopharmaceutical company, commenced voluntary Chapter 11 bankruptcy proceedings on August 28, 2026, according to reports from Reuters, BioSpace, and StreetInsider. The company also entered into an asset sale agreement with Teva Pharmaceuticals, which will act as the stalking-horse bidder for nearly all of BioXcel's assets, including its IGALMI franchise.

According to a Yahoo Finance report, Teva will pay $57.5 million upfront as the baseline offer, with potential additional payments. The sale is intended to be completed through a court-supervised process under Section 363 of the Bankruptcy Code, as noted in the company's SEC filing on August 27, 2026.

BioXcel's stock fell 7.82% on the day, closing at $0.719 per share, according to price data.

Why it matters

This is a going-concern event that could wipe out or heavily dilute equity holders while transferring key assets to a larger pharma buyer, as noted by market alerts summarized by BioPharmCatalyst. The company's shares have fallen about 55% over a recent period, as reported by Reuters.

For BioXcel, a company focused on developing treatments for neuroscience and immuno-oncology, this bankruptcy marks a significant turning point. The sale to Teva, if approved, would transfer its main product franchise to a major pharmaceutical company.

What this means

Chapter 11 bankruptcy allows a company to reorganize or sell its assets while under court protection from creditors. Here, BioXcel intends to sell nearly all its assets through a court-supervised process. A stalking-horse bidder, like Teva, sets a minimum bid for the assets, establishing a baseline price before an auction. This means other buyers can bid higher, but if no one does, Teva gets the assets at the set price.

The asset sale agreement includes the IGALMI franchise, which is a key product for BioXcel. IGALMI (dexmedetomidine) is a sublingual film used for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder. The future of this product, and any development pipeline, will depend on the outcome of the sale process.

Under Section 363 of the Bankruptcy Code, the sale must be approved by the bankruptcy court. The company stated it intends to complete the sale to maximize value for stakeholders, but the exact timeline and final price will depend on the auction process. Equity holders often receive little or nothing in such scenarios, as secured creditors are typically paid first.